<DOC>
	<DOCNO>NCT02085395</DOCNO>
	<brief_summary>To evaluate efficacy SR-T100 gel observe lesion size ( length x width x height ) human cutaneous squamous cell carcinoma situ ( Actinic Keratosis Bowen 's Disease ) reduce least 75 % .</brief_summary>
	<brief_title>Clinical Study Assessment SR-T100 Topical Gel Against Actinic Keratosis</brief_title>
	<detailed_description>An open phase II study ass efficacy safety topical SR-T100 gel treatment human cutaneous cell carcinoma situ ( Actinic Keratosis Bowen 's Disease ) . The primary efficacy endpoint defines proportion patient whose lesion size reduce least 75 % . The secondary efficacy endpoint include complete clearance rate proportion patient clinical visible AK/BD lesion treatment area , partial clearance rate proportion patient least 75 % reduction AK/BD lesion size teh treatment area , histological response rate proportion patient biopsy proven clearance AK BD situ . Safety evaluate clinically significant change occur baseline end study observe physical examination , vital sign , laboratory assessment AEs .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Bowen 's Disease</mesh_term>
	<criteria>Patients meet ALL inclusion criterion entry study : 1 . Male female ; age â‰§ 20 year old . 2 . Patients histologically confirm Squamous cell carcinoma situ ( AK BD ) target lesion . 3 . Patients measurable lesion 5mm large AK 10mm large BD . 4 . Patient performance status &lt; 2 ( ECOG ) . 5 . Patients sign approve write informed consent . Patients exclude study ANY follow reason : 1 . Patients histologic subtypes squamous cell carcinoma situ ( AK BD ) . 2 . Patients tumor extend oral cavity , nostril , eyelid , urethra , anus , vagina rectum . 3 . Patients grossly suspicious inflame node physical examination . 4 . Patients grossly infected tumor . 5 . Patients recurrent invasive squamous cell carcinoma . 6 . Patients history invasive malignancy , evidence malignancy present within past 5 year . Patients also exclude previous cancer treatment contraindicate protocol therapy . 7 . Use investigational drug 30 day screen . 8 . Pregnant lactate woman woman childbearing potential use inadequate contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Actinic Keratosis , AK , Bowen 's Disease , Bowen</keyword>
</DOC>